June 17 (Reuters) - Human Genome Sciences Inc:
* Human Genome Sciences and glaxosmithkline announce full presentation at eular
of bliss-76 phase 3 study results for Benlysta in systemic lupus
erythematosus
* Says Belimumab 10 mg/kg met its primary endpoint of superiority versus
placebo at week 52
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Human Genome Sciences and glaxosmithkline announce full presentation at eular
of bliss-76 phase 3 study results for Benlysta in systemic lupus
erythematosus
* Says Belimumab 10 mg/kg met its primary endpoint of superiority versus
placebo at week 52
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.